Literature DB >> 18438800

The discovery of antiviral agents: ten different compounds, ten different stories.

Erik De Clercq1.   

Abstract

This review article, while autobiographical to some extent, describes the discovery of ten (classes of) antiviral compounds that have made (or just did not make) it to the market for the therapy of viral infections, but each in its own way influenced the landscape of our dealing with virus infections: (i) valaciclovir, (ii) BVDU, (iii) DHPA, (iv) cidofovir, (v) adefovir, (vi) tenofovir, (vii) stavudine, (viii) HEPT, (ix) TIBO, and (x) AMD3100. Successful drug development, as is certainly true for antiviral drugs and exemplified for the acyclic nucleoside phosphonates cidofovir, adefovir and tenofovir, requires patience and perseverance, and a close continuous and dedicated interaction between Chemistry, Biology/Medicine and Industry.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438800     DOI: 10.1002/med.20128

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  19 in total

1.  Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.

Authors:  Sophie Duraffour; Graciela Andrei; Dimitri Topalis; Marcela Krečmerová; Jean-Marc Crance; Daniel Garin; Robert Snoeck
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 2.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

3.  Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet.

Authors:  Karoline Bleymehl; Jindrich Cinatl; Jonas Schmidt-Chanasit
Journal:  Med Microbiol Immunol       Date:  2011-03-04       Impact factor: 3.402

4.  Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.

Authors:  Orrette R Wauchope; Cameron Johnson; Pasupathy Krishnamoorthy; Graciela Andrei; Robert Snoeck; Jan Balzarini; Katherine L Seley-Radtke
Journal:  Bioorg Med Chem       Date:  2012-03-12       Impact factor: 3.641

5.  Efficacy of S-adenosylhomocysteine hydrolase inhibitors, D-eritadenine and (S)-DHPA, against the growth of Cryptosporidium parvum in vitro.

Authors:  Vlasta Ctrnáctá; Jason M Fritzler; Mária Surinová; Ivan Hrdý; Guan Zhu; Frantisek Stejskal
Journal:  Exp Parasitol       Date:  2010-04-20       Impact factor: 2.011

6.  DLK-Dependent Biphasic Reactivation of Herpes Simplex Virus Latency Established in the Absence of Antivirals.

Authors:  Sara Dochnal; Husain Y Merchant; Austin R Schinlever; Aleksandra Babnis; Daniel P Depledge; Angus C Wilson; Anna R Cliffe
Journal:  J Virol       Date:  2022-05-24       Impact factor: 6.549

7.  Evolution of an amino acid based prodrug approach: stay tuned.

Authors:  Ivan S Krylov; Boris A Kashemirov; John M Hilfinger; Charles E McKenna
Journal:  Mol Pharm       Date:  2013-01-22       Impact factor: 4.939

8.  Amidate Prodrugs of O-2-Alkylated Pyrimidine Acyclic Nucleosides Display Potent Anti-Herpesvirus Activity.

Authors:  Min Luo; Elisabetta Groaz; Robert Snoeck; Graciela Andrei; Piet Herdewijn
Journal:  ACS Med Chem Lett       Date:  2020-06-24       Impact factor: 4.345

9.  Regio- and enantioselective N-allylations of imidazole, benzimidazole, and purine heterocycles catalyzed by single-component metallacyclic iridium complexes.

Authors:  Levi M Stanley; John F Hartwig
Journal:  J Am Chem Soc       Date:  2009-07-01       Impact factor: 15.419

Review 10.  New strategies against drug resistance to herpes simplex virus.

Authors:  Yu-Chen Jiang; Hui Feng; Yu-Chun Lin; Xiu-Rong Guo
Journal:  Int J Oral Sci       Date:  2016-03-30       Impact factor: 6.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.